Influenza Types, Symptoms and Treatment

Authored by , Reviewed by Dr Laurence Knott | Last edited | Meets Patient’s editorial guidelines

Added to Saved items
This article is for Medical Professionals

Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find the Influenza and Flu-like Illness article more useful, or one of our other health articles.

Read COVID-19 guidance from NICE

Treatment of almost all medical conditions has been affected by the COVID-19 pandemic. NICE has issued rapid update guidelines in relation to many of these. This guidance is changing frequently. Please visit https://www.nice.org.uk/covid-19 to see if there is temporary guidance issued by NICE in relation to the management of this condition, which may vary from the information given below.

Synonym: flu

Influenza, also known as flu, is an acute respiratory illness due to infection with RNA viruses of the family Orthomyxoviridae (influenza viruses). It is highly infectious and transmission occurs via droplets, aerosols or direct contact with respiratory secretions from an infected person, and the usual incubation period is 1-3 days.

Uncomplicated influenza is defined as influenza presenting with fever, coryza, generalised symptoms (headache, malaise, myalgia, arthralgia) and sometimes gastrointestinal symptoms, but without any features of complicated influenza[2].

Complicated influenza is defined as influenza requiring hospital admission and/or with symptoms and signs of lower respiratory tract infection (hypoxaemia, dyspnoea, lung infiltrate), central nervous system involvement and/or a significant exacerbation of an underlying medical condition[2].

There are three serotypes - A, B and C[3]. Influenza A and B viruses cause most clinical disease:

  • A is the more frequent and the cause of major influenza outbreaks.
  • B tends to circulate with A in yearly outbreaks and causes less severe illness.
  • C tends to cause a mild or asymptomatic illness akin to the common cold.

Influenza A serotypes are further categorised by their surface antigens:

  • H: haemagglutinin - facilitates entry of the virus into the host respiratory cell.
  • N: neuraminidase - facilitates release of virions from the infected host cells.

There are 15 H and 9 N subtypes of the A virus in aquatic birds, which together with pigs (often termed the 'mixing vessel' for scrambling human and avian virus genetic material) are the natural reservoir of the virus.

The influenza virus undergoes minor mutations to one or both of its surface antigens - antigenic drift. This causes seasonal epidemics where people have only partial immunity from previous infection.

In influenza A alone, major and sudden changes in the H and N antigens produce a new virus subtype - antigenic shift. There is little population immunity to the new form and a major epidemic may ensue.

Influenza may be uncomplicated or complicated[1]:

  • Uncomplicated influenza is an acute respiratory infection caused by influenza A or B viruses that is usually self-limiting.
  • Complicated influenza is more severe and is associated more often with influenza A than influenza B infection. It is defined by signs and symptoms that involve the lower respiratory tract or central nervous system, or cause significant exacerbation of an underlying medical condition. Treatment may require more aggressive supportive care or hospitalisation.

Influenza-like illness presents with similar symptoms to influenza, but it is caused by a virus other than influenza A, B, or C - eg, respiratory syncytial virus.

Incidence of influenza 

Cases peak:

  • From December to March in temperate regions of the Northern hemisphere.
  • From May to September in the Southern hemisphere.
  • Throughout the year in tropical areas.

Up to 15% of the population can develop influenza in any year. There is a 10-20% seroconversion rate with or without symptoms. In an average year, there are 30-200 GP consultations for influenza or flu-like illnesses per 100,000 population per week, and over 200 during an epidemic[1].

The World Health Organization (WHO) has defined the criteria for a pandemic:

  • The disease must be new to the population - or at least a disease that has not surfaced for a long time.
  • This disease must be caused by disease-causing agents that infect humans, causing serious illness.
  • The agents must spread easily and sustainably among humans, causing a global outbreak.

There have been four pandemics in the last 100 years. The effects can be devastating; the 1918 outbreak killed around 21 million worldwide (that is 6 x more casualties than in the First World War):

  • The most recent was swine influenza virus (H1N1v), reaching pandemic proportions in June 2009 in the UK. Swine influenza A virus was quite different to previous viruses. The human community initially had little immunity to it. The young were at most risk and those aged over 60 years at least risk[4]. Epidemics occurred worldwide in 209 countries, with considerable morbidity and at least 14,142 deaths[5].
  • The National Pandemic Flu Service (NPFS) was established in the UK at the height of the pandemic; however, this was disbanded in February 2010 as the number of cases fell.
  • Continuing WHO surveillance reveals that in the winter of 2011-12 the majority of cases in Europe were associated with influenza A (H3N2)[6]. However, H1N1 was over-represented in severe cases compared with the other two circulating viruses in France, Ireland, Spain and the UK.

'At-risk group' includes people aged over 65 years, children aged under 6 months, pregnant women (at any stage of pregnancy, or women up to two weeks postpartum), and people with any of the following conditions:

  • Asplenia or dysfunction of the spleen.
  • Chronic respiratory disease, including:
    • Chronic obstructive pulmonary disease, chronic bronchitis and emphysema, bronchiectasis, cystic fibrosis, interstitial lung fibrosis, pneumoconiosis, and bronchopulmonary dysplasia.
    • Asthma that requires continuous or repeated use of inhaled or systemic corticosteroids or with previous exacerbations requiring hospital admission.
    • Children who have previously been admitted to hospital for lower respiratory tract disease.
  • Chronic heart disease - including congenital heart disease, hypertension with cardiac complications, chronic heart failure, and individuals requiring regular medication or follow-up for coronary heart disease.
  • Chronic kidney disease - including chronic kidney disease stage 3, 4 or 5, chronic kidney failure, nephrotic syndrome, and kidney transplantation.
  • Chronic liver disease - including cirrhosis, biliary atresia, and chronic hepatitis:
    • Chronic neurological conditions, including stroke and transient ischaemic attack. Conditions in which respiratory function may be compromised (for example, polio syndrome).
    • Individual assessment should also be considered in clinically vulnerable individuals including those with cerebral palsy, learning disabilities, multiple sclerosis and related or similar conditions; or hereditary and degenerative disease of the nervous system or muscles; or severe neurological disability.
  • Diabetes mellitus, including type 1 diabetes and type 2 diabetes.
  • Immunosuppression due to disease or treatment, including:
    • People undergoing chemotherapy (or radiotherapy) leading to immunosuppression.
    • People undergoing bone marrow transplant.
    • HIV infection (all stages).
    • Individuals treated with, or likely to be treated with, systemic steroids for more than one month at dosages equivalent to prednisolone 20 mg or more daily (at any age) or, for children weighing less than 20 kg, a dose of 1 mg or more per kg body weight per day.
    • Multiple myeloma.
    • Genetic disorders affecting the immune system (for example, IRAK-4, NEMO, complement disorder).
  • Morbid obesity (body mass index of 40 or more).

Residents of nursing homes are particularly at risk of serious complications because of their age, high rate of chronic disease and living in a closed community. In pregnant women there is a slight increase in perinatal mortality rate, as well as early and late fetal deaths.

Transmission is either by:

  • Droplet due to coughing/sneezing.
  • Direct nasal or eye contact with hands carrying the virus.

After an incubation period of one to three days the patient commonly presents with rapid onset of:

  • Anorexia.
  • Malaise.
  • Headache (retro-orbital).
  • Fever.
  • Myalgia.
  • Non-productive cough and sore throat.

Nasal discharge/obstruction and sneezing can occur but are not usually prominent features of the illness. Fever may not be seen in older patients. Gastrointestinal symptoms are not usual but may occur in a minority of patients.

Swine flu is similar to the usual human seasonal influenza infection, with most cases in adults and children being mild. Clinicians are encouraged to diagnose swine flu based on symptoms if there is a pyrexia (≥38°C), fever or history of fever and flu-like illness (two or more of the following symptoms: cough, sore throat, rhinorrhoea, widespread muscle and joint aches, headache). There may also be any of the following: fatigue, loss of appetite and sometimes diarrhoea, nausea, vomiting, otitis media and (rarely) cerebral irritability ± seizures[4].

Most symptoms typically last for 3-5 days but cough, tiredness and malaise may last for 1-2 weeks. Infectivity continues for five days from onset, although children can remain infectious for two weeks, and the severely immunocompromised can shed virus for weeks.

Atypical symptoms of flu in children

In H1N1 influenza these include haematemesis, photophobia, chest pain, epistaxis, croup, apnoea and rigors. Very young children and babies can present with apnoea, reduced tone and poor feeding (without classical influenza features) and may exhibit a sudden severe collapse (apparent life-threatening episode)[4].

With all influenzas, neonates and infants may present with lethargy, poor feeding, apnoea or fever, pneumonia or otitis media. Drowsiness occurs in 50% of children aged <4 years, and in around 10% of children aged 4-15 years. It is uncommon in adults.

The most important are listed below:

In pregnant women, always consider pulmonary embolus (chest pain, tachypnoea and tachycardia) and pre-eclampsia (epigastric pain, headaches and elevated blood pressure).

The diagnosis is a clinical one so investigations are usually reserved for community surveillance purposes. Available tests include:

  • Direct viral culture of nasopharyngeal swabs/aspirates.
  • Immunofluorescence of nasopharyngeal swabs/aspirates.
  • Acute and convalescent sera, 10-14 days apart.
  • Polymerase chain reaction.
  • Rapid bedside antigen tests. These currently have low positive predictive values[7].

General measures

In otherwise healthy individuals with uncomplicated illness, self-management is recommended, including resting at home, increased fluid intake, analgesics and antipyretics.

NB: aspirin should be avoided in children aged <16 years, due to the danger of Reye's syndrome.

Pharmacological[8]

The antivirals oseltamivir and zanamivir are used for both treatment and post-exposure prophylaxis of influenza, although there is evidence that some strains of influenza are more likely to develop resistance to oseltamivir. The risk of developing oseltamivir resistance is greater for influenza A (H1N1pdm09) compared to other strains and the risk of resistance is higher in patients who are severely immunosuppressed. Amantadine hydrochloride is not recommended for the treatment or post-exposure prophylaxis of influenza A.

The use of antivirals in the management of influenza infection (for individuals and in populations) should be selective and appropriate[9].

  • Where treatment with oseltamivir is indicated, it should be started as soon as possible, ideally within 48 hours of symptom onset. There is evidence to suggest that the risk of mortality may be reduced even if treatment is started up to five days after symptom onset, but treatment initiation beyond 48 hours of onset is unlicensed.
  • Where treatment with inhaled zanamivir is indicated, it should also be started as soon as possible, ideally within 48 hours (36 hours in children) of symptom onset. Treatment initiation beyond this time is unlicensed.
  • Where treatment with intravenous zanamivir is indicated, it should be commenced as soon as possible and within six days of symptom onset.

Uncomplicated influenza

  • If otherwise healthy (excluding pregnant females), no antiviral treatment is usually needed. Oseltamivir should be offered to those considered to be at serious risk of developing complications.
  • For patients in an at-risk group (including pregnant females but excluding those who are severely immunosuppressed), offer oseltamivir and do not wait for laboratory test results to treat. For pregnant females who meet additional criteria for requiring zanamivir first-line, treatment should be discussed with a local infection specialist.
  • For severely immunosuppressed patients, consider the subtype of influenza causing the infection, or if not yet known, take into account the current dominant circulating strain. Offer oseltamivir first-line unless the strain has a higher risk for oseltamivir resistance, in which case inhaled zanamivir should be offered. For patients unable to use inhaled zanamivir due to underlying severe respiratory disease or inability to use the device (including children under 5 years), offer oseltamivir and assess response to therapy.
  • For suspected or confirmed oseltamivir-resistant influenza, offer inhaled zanamivir. For patients unable to use inhaled zanamivir, consider intravenous zanamivir (this is an unlicensed indication).

Complicated influenza

  • All patients should be tested and treated, often in hospital. Do not wait for laboratory test results to treat. For patients who are not severely immunosuppressed, oseltamivir should be offered first-line. If there is a risk of reduced gastrointestinal absorption, or if initial oseltamivir treatment is unsuccessful, offer inhaled zanamivir. For pregnant females who meet additional criteria for requiring zanamivir first-line, treatment should be discussed with a local infection specialist.
  • For severely immunosuppressed patients, consider the dominant circulating strain of influenza to guide treatment. Offer oseltamivir first-line unless the strain has a higher risk for developing oseltamivir resistance, in which case inhaled zanamivir should be offered.
  • For patients with suspected or confirmed oseltamivir-resistant influenza, offer inhaled zanamivir.
  • For patients unable to use inhaled zanamivir, or for those with severe complicated illness such as multiorgan failure, consider intravenous zanamivir.

A Cochrane review found[10]:

  • Oseltamivir and zanamivir have small, non-specific effects on reducing the time to alleviation of influenza symptoms in adults, but not in asthmatic children.
  • Using either drug as prophylaxis reduces the risk of developing symptomatic influenza.
  • Treatment trials with oseltamivir or zanamivir do not settle the question of whether the complications of influenza (such as pneumonia) are reduced.
  • The use of oseltamivir increases the risk of adverse effects, such as nausea, vomiting, psychiatric effects and renal events in adults and vomiting in children.
  • Lower bioavailability may explain the lower toxicity of zanamivir compared to oseltamivir. 

Oseltamivir may be ineffective in neonates but can be used for treatment or post-exposure prophylaxis of influenza in children under 1 year of age[8].

Safety data are limited but either oseltamivir or zanamivir can be used in women who are pregnant or breastfeeding when the potential benefit outweighs the risk such as during a pandemic. Oseltamivir is preferred for women who are breastfeeding.

National Institute for Health and Care Excellence (NICE) guidance for the treatment of influenza[11]

  • The guidance does not cover treatment in a pandemic, an impending pandemic or a widespread epidemic of a new strain of influenza to which there is little or no immunity in the community.
  • Amantadine is not recommended for treatment of influenza.
  • When influenza is circulating in the community, either oseltamivir or zanamivir is recommended for the treatment of influenza in at-risk patients who can start treatment within 48 hours (within 36 hours for zanamivir in children) of the onset of symptoms.
  • During local outbreaks of influenza-like illness, when there is a high level of certainty that influenza is present, either oseltamivir or zanamivir may be used for treatment in at-risk patients living in long-term residential or nursing homes.
  • At-risk patients include those aged over 65 years or those who have one or more of the following conditions:
    • Chronic respiratory disease, including asthma and chronic obstructive pulmonary disease (COPD).
    • Chronic heart disease.
    • Chronic kidney disease.
    • Chronic liver disease.
    • Chronic neurological disease.
    • Immunosuppression.
    • Diabetes mellitus.
    • Pregnancy.

Follow-up

Consider follow-up (particularly in frail people) after about one week, to confirm symptoms are improving and to exclude the development of secondary complications.

Advise the person that they should seek urgent medical attention if they develop shortness of breath or pleuritic chest pain, or if they start to cough up blood.

Arrange a follow-up appointment if there is no improvement after one week (that is, they are still significantly ill) or if they are deteriorating.

Have a lower threshold for seeking help if they are caring for a young child or baby with influenza, as children cannot accurately communicate their symptoms.

Estimates of excess winter deaths potentially attributable to influenza since 2004 in England and Wales range from not determined (in 2005-6 and 2006-7) to 10,351 (in 2008-9). The highest estimate since the mid-1990s was 21,497 for the 1999-2000 influenza season.

The risk of serious illness from influenza is higher amongst children under 6 months of age, older people and those with underlying health conditions (such as respiratory or cardiac disease, chronic neurological conditions or immunosuppression) and pregnant women.

Influenza during pregnancy may also be associated with perinatal mortality, prematurity, smaller neonatal size and lower birth weight.

Typically, seasonal influenza (H3N2) has a greater effect on mortality rates in the elderly but H1N1 tends to affect children and young adults[12].

See also the separate Influenza Vaccination article.

Post-exposure prophylaxis[8]

Contacts in an at-risk group who are not adequately protected through vaccination (either due to infection by a different circulating strain or exposure within 14 days post-vaccination), should be offered prophylaxis following exposure to a person in the same household or residential setting with influenza-like illness (when influenza is circulating). Certain populations that are susceptible to localised outbreaks (such as those in care homes, prisons or detention centres), may be considered for antiviral prophylaxis regardless of vaccination status.

Prophylaxis should be started as soon as possible following exposure, ideally within 48 hours for oseltamivir and 36 hours for inhaled zanamivir. Initiation beyond these times is unlicensed and specialist advice should be sought.

For patients in an at-risk group (including pregnant females but excluding severely immunosuppressed patients and children aged under 5 years), offer oseltamivir first-line regardless of the risk for resistance of the circulating or index case strain. For pregnant females who meet additional criteria for requiring zanamivir first-line, treatment should be discussed with a local infection specialist. For patients exposed to a strain with suspected or confirmed oseltamivir resistance, offer inhaled zanamivir.

For severely immunosuppressed patients (excluding children aged under 5 years), offer oseltamivir if the risk for oseltamivir resistance is low. However, if the risk for oseltamivir resistance is high, suspected or confirmed, offer inhaled zanamivir. For patients at higher risk of oseltamivir resistance who are unable to use inhaled zanamivir (due to underlying severe respiratory disease or inability to use the device), offer oseltamivir and advise patients to seek immediate medical attention if symptoms develop subsequently. For patients exposed to suspected or confirmed oseltamivir-resistant influenza who are unable to use inhaled zanamivir, specialist advice should be sought and patients monitored closely for influenza-like illness, with arrangements made for prompt treatment if symptoms develop.

For children aged under 5 years in an at-risk group (including severely immunosuppressed children), offer oseltamivir first-line regardless of the risk of resistance for the circulating or index case strain. However, if the child is exposed to suspected or confirmed oseltamivir-resistant influenza, monitor closely for influenza-like illness and promptly commence treatment if symptoms develop. Seek specialist advise if the child is severely immunosuppressed.

NICE guidance for prophylaxis of influenza[13]

  • The guidance does not cover treatment in a pandemic, an impending pandemic or a widespread epidemic of a new strain of influenza to which there is little or no immunity in the community.
  • Amantadine is not recommended for prophylaxis of influenza.
  • Oseltamivir or zanamivir are not recommended for seasonal prophylaxis against influenza.
  • When influenza is circulating in the community, either oseltamivir or zanamivir is recommended for post-exposure prophylaxis in at-risk patients who are not effectively protected by influenza vaccine and who have been in close contact with someone suffering from influenza-like illness in the same household or residential setting.
  • Oseltamivir should be given within 48 hours of exposure to influenza while zanamivir should be given within 36 hours of exposure to influenza.
  • During local outbreaks of influenza-like illness, when there is a high level of certainty that influenza is present, either oseltamivir or zanamivir may be used for post-exposure prophylaxis in at-risk patients who are living in long-term residential or nursing homes, regardless of influenza vaccination status.

Are you protected against flu?

See if you are eligible for a free NHS flu jab today.

Check now

Further reading and references

  1. Influenza - seasonal; NICE CKS, August 2020 (UK access only).

  2. HPA guidance on use of antiviral agents for the treatment and prophylaxis of influenza 2011-12; Health Protection Agency (December 2011 - Reviewed October 2012) (archived content)

  3. Influenza: the Green Book, Chapter 19; Public Health England

  4. Pandemic H1N1 2009 influenza: clinical management guidelines for adults and children; Dept of Health (archived content)

  5. Pandemic (H1N1) 2009; World Health Organization

  6. Weekly epidemiological record. Review of the 2011–2012 winter influenza season; World Health Organization, June 2012

  7. Mahony AA, Cheng AC, Olsen KL, et al; Diagnosing swine flu: the inaccuracy of case definitions during the 2009 Influenza pandemic, an attempt at refinement, and the implications for future planning. Other Respi Viruses. 2012 Jun 19.

  8. British National Formulary (BNF); NICE Evidence Services (UK access only)

  9. Guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza; UK Health Security Agency (November 2021).

  10. Jefferson T, Jones MA, Doshi P, et al; Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2014 Apr 10(4):CD008965. doi: 10.1002/14651858.CD008965.pub4.

  11. Amantadine, oseltamivir and zanamivir for the treatment of influenza; NICE Technology Appraisal Guidance, February 2009

  12. Scalera NM, Mossad SB; The first pandemic of the 21st century: a review of the 2009 pandemic variant influenza A (H1N1) virus. Postgrad Med. 2009 Sep121(5):43-7.

  13. Oseltamivir, amantadine (review) and zanamivir for the prophylaxis of influenza; NICE Technology Appraisal Guidance, September 2008

newnav-downnewnav-up